Abstract
Commercially available transplantable adenocarcinoma (T1703) in Jackson Laboratory mice (DBA/1J) were studied using T2B2 to carry 105B for 105B thermal neutron capture therapy. The UCLA thermal neutron fluence was 2.7 × 10121₀n/cm2 and exposure was total body. There were no signs of typical radiation damage to skin, gastrointestinal tract, or hematopoietic system. The results indicated a significant (p= < 0.01) increase in mean survival of 15.85 days between T2B2 and Tc controls. Retardation in neoplastic growth was observed, and apparent permanent regression was achieved in 22.7% of the T2B2-treated animals.

This publication has 0 references indexed in Scilit: